MARKET WIREYahoo Finance • 22h ago
What iRadimed (IRMD) Said on Its Q3 Earnings CallYahoo Finance report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
Why IRMD Stock surged +3.57% Today — RQD Quant Desk Flash
$79.42 +3.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $79.78
iRadimed Corporation (IRMD) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $980.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IRMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, iRadimed Corporation (NASDAQ: IRMD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $79.42 (+3.57% 1D, market cap $980.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, IRMD ranks #206 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IRMD compare to IART and SIBN in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), IRMD carries a Roarable D+ (55/100 RQD), trailing P/E of 48.8x, gross margin of 76.7%, and ROIC of 37.7%. By comparison, IART (Integra LifeSciences Holdings Corporation) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $992.0M) and SIBN (SI-BONE Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -10.3%, cap $951.5M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IRMD?
▼
Per IRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001325618), iRadimed Corporation generated $83.8M in revenue (+14.4% YoY), $22.5M in net income, and $17.2M in free cash flow against $108.8M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (76.7% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $79.78 (+0.45%)🧬 Disciplined Float (-0.32% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 20.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-1.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRMD)Realized 20D OHLCV Swing Band: ±6.5%
Deterministic 5-Pillar Attribution (55/100 Composite)
🔍 WHY IRMD SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (29% of score)
SEC XBRL FY 2025 (10-K): 20.5% FCF Margin ($17.2M FCF) & 76.7% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (25% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$89.65-1.6% Next Q
63
Q2 (-2Q)Grade C$88.24-4.9% Next Q
60
Q3 (-1Q)Grade C$83.95-5.4% Next Q
58
CurrentGrade D+$79.42-0.5% Hist 90D α
55
Trajectory: C+ (63) → D+ (55)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the IRMD Bull Thesis Could Fail
Even with a 55/100 (D+) score, IRMD faces multiple-compression risk if 48.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($85.41) or 200D SMA ($92.33) invalidates the momentum regime and cuts Target Base ($78.35) toward Bear Floor ($61.11).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IRMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IRMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IRMD Stock surged +3.57% Today — RQD Quant Desk Flash
iRadimed Corporation (IRMD) surged +3.57% to $79.42, trading at 10% of its 52-week range ($76.35 – $107.9). Stretched risk/reward at 49x P/E (38% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 10% of its 52-week range ($76.35 – $107.9) with RSI-14 at 37 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.5% around $79.42 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 76.7% gross margin and $17.2M annual free cash flow.
Live IRMD Headlines & Catalysts
MARKET WIRETradingView • 1d ago
iRadimed Corporation Estimates – NASDAQ:IRMDTradingView report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREmarketscreener.com • 1d ago
(IRMD) IRADIMED CORPORATION Expects Q4 Revenue Range $25.0M - $26.5Mmarketscreener.com report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
At US$83.95, Is IRADIMED CORPORATION (NASDAQ:IRMD) Worth Looking At Closely?Simply Wall St report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
BlackRock reports voting power over 614,615 Iradimed (IRMD) shares alongside a passive stake.Stock Titan report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREQuiver Quantitative • 1d ago
Iradimed Q3 Revenue Rises 14% to $24.2 MillionQuiver Quantitative report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.marketscreener.com • 1d ago
Earnings Flash (IRMD) IRADIMED CORPORATION Reports Q3 Revenue $24.2M, vs. FactSet Est of $23.5Mwww.marketscreener.com report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
iRadimed (IRMD) Rises 1.83% to $87.45, Sitting Midway Between Support and Resistance - Covered Call ETFhttps://www.siam.in/ report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 2d ago
IRadimed (IRMD) Stock Drops After Q3 Earnings Fail To Clear High BarIRADIMED came into this earnings season priced for excellence, trading on a rich P/E and riding years of steady profit expansion. Then Q3 2026 hit and the stock dropped about 11% in a single session. That sharp move jars
CATALYSTYahoo • 3d ago
Is IRADIMED (IRMD) Fully Priced Based On Future Cash Flow?IRADIMED has pulled back in the short term after a strong multi year run. This puts the spotlight squarely on whether the current share price is properly anchored to the cash it can generate. With the analysis lens fixed
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IRMD)
- ✓Walkthrough of IRMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.48%📐 HORIZONTAL RANGE
2026-11-03O $85.74H $85.74L $76.68C $79.42VOL 218.1K
RES: $91.74SUP: $76.07SMA50: $85.41SMA200: $92.33
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
35.7%/yr Implied 5Y Growth
vs. +14.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on IRMD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IRMD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRMD)
Health Care Rank #206 of 1015
⚔️ IART vs IRMD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IRMD vs. IART, SIBN, BBNX, SGP)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, iRadimed Corporation (IRMD) ranks #206 by composite RQD confidence (55/100, grade D+) and #358 by equity capitalization ($980.5M). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently leads its immediate peer cohort in composite quantitative strength at 55/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IRMD
ACTIVE
iRadimed Corporation | D+ | 55/100 | 48.8x | 76.7% | 37.7% | +3.57% | $980.5M | Benchmark Subject |
| IART Integra LifeSciences Holdings Corporation | E | 19/100 | — | 50.9% | -35.0% | +6.75% | $992.0M | /iart-vs-irmd → |
| SIBN SI-BONE Inc. | D+ | 52/100 | — | 79.6% | -10.3% | -4.76% | $951.5M | /sibn-vs-irmd → |
| BBNX Beta Bionics Inc. | D- | 36/100 | — | 55.4% | -22.1% | -5.07% | $910.6M | /bbnx-vs-irmd → |
| SGP SpyGlass Pharma Inc. | D- | 43/100 | — | — | -35.0% | +4.34% | $1.08B | /sgp-vs-irmd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001325618 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), iRadimed Corporation (IRMD) reported GAAP revenue of $83.8M (+14.4% vs. FY2024 revenue of $73.2M , and +27.8% cumulative change since FY2023) , GAAP net income of $22.5M, operating cash flow of $24.9M, and free cash flow of $17.2M (-2.5% YoY). On the balance sheet, IRMD closed FY2025 with $108.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $83.8M | $22.5M | $24.9M | $17.2M | $108.8M | — |
| FY2024 (FY) | 2024-12-31 | $73.2M | $19.2M | $25.6M | $17.6M | $98.3M | — |
| FY2023 (FY) | 2023-12-31 | $65.6M | $17.2M | $13.5M | $13.5M | — | — |
3. IRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, iRadimed Corporation (NASDAQ: IRMD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $79.42 (+3.57% 1D, market cap $980.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, IRMD ranks #206 in composite RQD confidence.
How does IRMD compare to IART and SIBN in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), IRMD carries a Roarable D+ (55/100 RQD), trailing P/E of 48.8x, gross margin of 76.7%, and ROIC of 37.7%. By comparison, IART (Integra LifeSciences Holdings Corporation) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $992.0M) and SIBN (SI-BONE Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -10.3%, cap $951.5M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IRMD?
Per IRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001325618), iRadimed Corporation generated $83.8M in revenue (+14.4% YoY), $22.5M in net income, and $17.2M in free cash flow against $108.8M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (76.7% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IRMD trading relative to its 50-day, 200-day, and 52-week technical levels?
IRMD last traded at $79.42 (+3.57% on volume of 203,527 shares), positioning the stock -7.01% below its 50-day simple moving average ($85.41) and -13.98% below its 200-day simple moving average ($92.33). Across its 52-week range of $76.35 to $107.90, IRMD sits at the 9.7% percentile with a 14-day RSI of 37.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($74.26 to $84.58).
ROARABLE RATING BRIEF • RQD 55/100 (D+)
✓ SEC XBRL & RQD VERIFIED
IRMD — iRadimed Corporation: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
iRadimed Corporation (IRMD) earns a live Roarable RQD composite score of 55/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $79.42 (+3.57% 1D, market capitalization $980.5M).
- Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 37.7%, gross margin of 76.7%, operating margin of 31.2%, and free cash flow yield of 1.57%.
- Whale 13F & Options Flow (3/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (9/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 8/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
IRadimed Corporation is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry..1B. Specific product lines, customer base, and revenue model details are — Gross margin of 76.7% and operating margin of 31.2% are reported in the market data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), iRadimed Corporation (IRMD) reported $83.8M in annual revenue (up from $73.2M in FY2024, +14.4% YoY) and $22.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($65.6M revenue, $17.2M net income) through FY2025, IRMD scaled operating cash flow to $24.9M and free cash flow to $17.2M, backed by $108.8M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D+ • RQD 55/100): Strong cash generator (76.7% gross margin)—profits are backed by real money, not accounting tricks. Free cash flow yield of 1.57% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $76.35 – $107.90 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 48.8x trailing P/E and 31.9x EV/EBITDA against 31.2% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Medical/Dental Instruments (Health Care), IRMD carries a macro regime beta of 1.00 and gross margin of 76.7%.
- Key Question #1: Can IRMD sustain or expand its 31.2% operating margin and 37.7% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $83.8M and free cash flow of $17.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is IRMD's 41.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
IRMD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for iRadimed Corporation (IRMD) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 22h ago
What iRadimed (IRMD) Said on Its Q3 Earnings Call Yahoo Finance report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
iRadimed Corporation Estimates – NASDAQ:IRMD TradingView report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE marketscreener.com • 1d ago
(IRMD) IRADIMED CORPORATION Expects Q4 Revenue Range $25.0M - $26.5M marketscreener.com report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
At US$83.95, Is IRADIMED CORPORATION (NASDAQ:IRMD) Worth Looking At Closely? Simply Wall St report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
BlackRock reports voting power over 614,615 Iradimed (IRMD) shares alongside a passive stake. Stock Titan report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Quiver Quantitative • 1d ago
Iradimed Q3 Revenue Rises 14% to $24.2 Million Quiver Quantitative report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 1d ago
Earnings Flash (IRMD) IRADIMED CORPORATION Reports Q3 Revenue $24.2M, vs. FactSet Est of $23.5M www.marketscreener.com report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
iRadimed (IRMD) Rises 1.83% to $87.45, Sitting Midway Between Support and Resistance - Covered Call ETF https://www.siam.in/ report covering iRadimed Corporation (IRMD) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
IRMD Bull vs. Bear Conversation Board — What's Your Call at $79.42?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IRMD 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $92.02 (+20.0%)
📌 Pinned Debate A 37.7% ROIC and 26.8% net margin show a highly profitable cash engine that has grown revenue from $65.6M to $83.8M over two years.
Long IRMD at $76.68 targeting $92.02. A 37.7% ROIC and 26.8% net margin show a highly profitable cash engine that has grown revenue from $65.6M to $83.8M over two years.. Institutional whale score is 3/20 and the risk/reward vs. the $76.35 52-week low is skewed heavily in favor of bulls.
ArenaChamp_24 🐂 BULL
@DeltaGamma_99 Agree on the RQD 55/100 quality, though with 1.0 beta I'm scaling in with half-size at $76.68 and keeping dry powder in case we test $71.31.
BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH
🎯 Target: $63.64 (-17.0%)
Spot @ $76.68 At a 48.8 P/E (TTM) and 31.9 EV/EBITDA against a 1.57% FCF yield, the valuation leaves little room for earnings disappointment.
Fading this rally in IRMD at $76.68. At a 48.8 P/E (TTM) and 31.9 EV/EBITDA against a 1.57% FCF yield, the valuation leaves little room for earnings disappointment.. With a beta of 1.0 and the stock sitting at $76.68 (52-wk range $76.35–$107.90), the easy multiple expansion is already priced in.